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Tumor progression has been linked to changes in the stromal envi-
ronment. Myofibroblasts are stromal cells that are often increased 
in tumors but their contribution to cancer progression is not well 
understood. Here, we show that the secretomes of myofibroblasts 
derived from gastric cancers [cancer-associated myofibroblasts 
(CAMs)] differ in a functionally significant manner from those 
derived from adjacent tissue [adjacent tissue myofibroblasts 
(ATMs)]. CAMs showed increased rates of migration and pro-
liferation compared with ATMs or normal tissue myofibroblasts 
(NTMs). Moreover, conditioned medium (CM) from CAMs signif-
icantly stimulated migration, invasion and proliferation of gastric 
cancer cells compared with CM from ATMs or NTMs. Prot-
eomic analysis of myofibroblast secretomes revealed decreased 
abundance of the extracellular matrix (ECM) adaptor protein 
like transforming growth factor-β-induced gene-h3 (TGFβig-h3) 
in CAMs, which was correlated with lymph node involvement 
and shorter survival. TGFβig-h3 inhibited IGF-II-stimulated 
migration and proliferation of both cancer cells and myofibro-
blasts, and suppressed IGF-II activation of p42/44 MAPkinase; 
TGFβig-h3 knockdown increased IGF-II- and CM-stimulated 
migration. Furthermore, administration of TGFβig-h3 inhibited 
myofibroblast-stimulated growth of gastric cancer xenografts. We 
conclude that stromal cells exert inhibitory as well as stimulatory 
effects on tumor cells; TGFβig-h3 is a stromal inhibitory factor 
that is decreased with progression of gastric cancers.
Introduction
Stromal cells are well recognized to play influential roles in determin-
ing tumor progression (1–4). Cancer-associated fibroblasts (CAFs) 
are an important stromal cell type with distinct properties (5–7) and 
recent work indicates that differences in gene expression in the stro-
mal compartment predict clinical outcome and response to therapy (8–
10). Many different stromal cell factors may contribute to the tumor 
microenvironment (6,11–14), but the changes that occur in stromal 
cell function with cancer progression remain poorly understood.
Myofibroblasts, also sometimes called activated fibroblasts, are 
considered to be a subclass of CAFs. They are present in normal tis-
sue in low density, increase with inflammation, infection or tissue 
damage (15) and are responsible for secretion of extracellular matrix 
(ECM) proteins, matrix metalloproteinases, protease inhibitors, 
growth factors, cytokines and chemokines as well as cyclo-oxygenase 
products. Epigenetic changes have been detected in cancer-associated 
myofibroblasts (CAMs) from gastric adenocarcinoma compared with 
myofibroblasts derived from adjacent tissue (ATMs) providing a basis 
for understanding how gastric CAMs might differ from other myofi-
broblasts (16).
Gastric cancer is the second most frequent cause of cancer-related 
mortality in males worldwide, and is frequently associated with 
Helicobacter pylori infection of the gastric corpus (17,18). The pro-
gression to cancer occurs over many decades and is characterized by 
preneoplastic changes including gastritis, atrophy, intestinal meta-
plasia and spasmolytic peptide-expressing metaplasia, and dysplasia 
(19,20). Infection is also associated with increases in gastric myofi-
broblasts that may reflect increased insulin-like growth factor (IGF) 
activity through matrix metalloproteinase-7 degradation of IGF-bind-
ing protein-5 (21–23), as well as recruitment of bone marrow-derived 
cells (24,25).
Recent studies suggest a role in cancer progression for the ECM 
adaptor protein transforming growth factor-β-induced gene-h3 
(TGFβig-h3; also known as βig-h3, TGFBI, βIGH3, keratoepithe-
lin and MP78/70). The latter is a 68 kDa protein with four fasciclin-
like domains and an RGD domain in the C-terminal region; it binds 
ECM proteins including collagen, fibronectin and laminin (26,27). 
TGFβig-h3 suppresses the growth of Chinese hamster ovary cells in 
nude mice (28) and mice null for TGFβig-h3 develop spontaneous 
tumors in a variety of organs (29); loss of TGFβig-h3 in ovarian can-
cer is associated with resistance to taxanes (30). However, the role 
of TGFβig-h3 in cancer remains uncertain since expression has been 
associated with increased aggressiveness of liver and colon cancer 
cells (31,32). In this study, we have characterized a panel of CAMs 
from gastric cancers and compared their secretomes with those of 
myofibroblasts from adjacent tissue. We report here that decreased 
secretion of TGFβig-h3 in CAMs is associated with lymph node 
involvement and shorter survival, and we show that TGFβig-h3 
suppresses cancer cell migration and inhibits growth in a model of 
stroma-stimulated cancer growth in vivo.
Materials and methods
Materials
Human recombinant TGFβig-h3 and IGF-II were obtained from R&D Sys-
tems (Abingdon, Oxon, UK); siRNA for TGFβig-h3, and control scrambled 
sequences were purchased from Ambion (Austin, TX). Antibodies for alpha-
smooth muscle actin (α-SMA), vimentin and desmin were purchased from 
RDI (Flanders, NJ); antibody for pancytokeratin was used from Dako (Ely, 
Cambridgeshire, UK). Antibodies for TGFβig-h3, and GAPDH were obtained 
from R&D Systems and Biodesign (Saco, ME), respectively. Cleaved cas-
pase-3 antibody was purchased from New England Biolabs (Hertfordshire, 
UK). Antibodies for Bax, Bim and Bcl-2 were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA), Abcam (Cambridge, UK) and Dako, respect-
ively. Antibodies for total and phosphorylated p42/44 were obtained from Cell 
Signaling (Beverly, MA). All other chemicals were purchased from Sigma 
(Poole, Dorset, UK).
Generation of human primary myofibroblasts
Human primary myofibroblasts were derived from resected gastric cancers 
(CAM) and adjacent tissue (ATM) obtained from patients undergoing surgery 
for gastric cancer (Supplementary Table 1, available at Carcinogenesis Online 
(16,23)). Tumor and adjacent tissues were characterized using the TNM 
classification (Supplementary Methods, available at Carcinogenesis Online) 
Abbreviations: ATM, adjacent tissue myofibroblasts; CAF, cancer-associ-
ated fibroblasts; CAM, cancer-associated myofibroblasts; IGF-II, insulin-like 
growth factor-II; NTM, normal tissue myofibroblasts; TGFβig-h3, transform-
ing growth factor-β-induced gene-h3.
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for gastric cancer (33). Normal myofibroblasts (NTM) were generated from 
deceased transplant donors with normal gastric morphology. Tumor and 
normal tissues were characterized using a scoring system for myofibroblast 
morphology, architecture and number (Supplementary Methods, available at 
Carcinogenesis Online). For histopathological assessments, myofibroblasts 
were defined as stellate/spindle-shaped cells with consistent α-SMA and 
vimentin co-expression. Smooth muscle fibers were excluded based on their 
characteristic morphology. This study was approved by the Ethics Committee 
of the University of Szeged, Hungary. Myofibroblasts were cultured as 
described previously (23) and were used between passages 3 and 10. 
Conditioned medium (CM) was prepared from 1  106 myofibroblasts plated 
in 10 cm diameter dishes to give 80–90% confluency and collected after 24 h 
in 10 ml serum-free media.
Human gastric carcinoma cell lines
AGS cells (ATCC, Manassas, VA) and MKN45 gastric carcinoma cells 
(RIKEN, Ibaraki, Japan) were cultured as described previously (34).
Immunohistochemistry
Formalin-fixed, paraffin-embedded, tissue sections were processed for detec-
tion of α-SMA, vimentin and desmin after antigen recovery using Multivision 
Polymer Detection System (Thermo Scientific). For immunocytochemistry, 
cells were cultured in chamber slides, stained with α-SMA, vimentin, desmin 
and pancytokeratin followed by incubation with the appropriate fluorescein or 
Texas Red-labeled secondary antibodies raised in donkey (Jackson Immunore-
search, Soham, UK), and mounted with Vectashield containing 4ʹ,6-diamidino-
2-phenylindole (Vector Laboratories, Peterborough, UK). For visualization of 
F-actin, the primary antibody was substituted with 50 µg/ml tetramethyl rhoda-
mine iso-thiocyanate-conjugated phalloidin. Slides were viewed using a Zeiss 
Axioplan-2 microscope (Zeiss Vision, Welwyn Garden City, UK). Images 
were captured using a JVC-3 charge-coupled device camera at 40 magnifi-
cation with KS300 software (Imaging Associates, Bicester, Oxfordshire, UK).
Migration, invasion, proliferation and apoptosis assays
Migration and invasion of primary human gastric myofibroblasts or cancer cells 
were studied in 8 µm pore chambers (BD Control Cell Culture Inserts or BD 
BioCoat Matrigel Invasion Chambers, respectively; BD Biosciences, Oxford, 
UK) as described previously (23,35). Incorporation of [3H]-thymidine by human 
gastric myofibroblasts or AGS cells was studied using methods described previ-
ously (34). Additionally, proliferation was assessed by incorporation of BrdU 
(3 ng/ml) as described previously (23), or EdU (10 µM) according to the manu-
facturer’s instruction (Invitrogen, Paisley, UK). Apoptosis was studied using 
cleaved caspase-3 antibody (New England Biolabs (Hertfordshire, UK).
Isobaric tagging for relative and absolute quantitation
Myofibroblast CM was concentrated to 500 µl, acetone precipitated and resus-
pended in 0.5 M triethylammonium bicarbonate (TEAB) in 0.1% sodium 
dodecyl sulfate. Myofibroblasts were lysed directly in TEAB/sodium dodecyl 
sulfate. Samples (100 µg) were labeled using the 4-plex iTRAQ® kit (AB 
SCIEX, Foster City, CA) according to manufacturer’s instructions. Labeled 
samples were pre-fractionated using a PolyLC PolySULFOETHYL A (4.6  
200 mm i.d.) cation exchange column using an Agilent 1100 HPLC system 
(Agilent Technologies, Santa Clara, CA). Samples were then analyzed using 
an LC Packings Ultimate nano-LC system run in-line with a QStar Pulsar i 
mass spectrometer (AB Sciex). Protein identification and quantification were 
performed using the ProteinPilot™ v3.0.1 software (AB Sciex). The Paragon 
algorithm was selected as the default search program, with the digestion agent 
set as trypsin and cysteine modification as methyl methanethiosulfonate. Pro-
teins were reported based on the assignment of at least two tryptic peptides 
with a confidence >95%, or on the assignment of one tryptic peptide with a 
confidence >99% and a local false discovery rate calculated using the PSPEP 
algorithm of <1%. Proteins exhibiting a differential abundance in CAMs 
versus ATMs were calculated only on the assignment of at least two tryptic 
peptides using a Pro Group™ algorithm of ProteinPilot™. When comparing 
groups of patients, proteins that were identified in >80% in one of the groups 
were used in the analysis. Pathway analysis was performed using MetaCore® 
(GeneGo, St Joseph, MI).
Western blotting
Myofibroblast cell extracts were prepared in RIPA buffer containing protease 
and phosphatase inhibitors and proteins resolved by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and processed for western blotting as 
described previously (22).
Knockdown of TGFβig-h3
Knockdown of TGFβig-h3 was performed using 35 µM of TGFβig-h3 siRNA, 
and negative control scrambled RNA, for 72 h by nucleofection using the 
NHDF transfection kit (Amaxa; Köln, Germany). The efficiency of the knock-
down was verified by western blotting.
Xenograft studies in SCID mice
To study the effect of TGFβig-h3 on xenograft growth, 6- to 8-week-old 
immunocompromised mice (SCID, Jackson Laboratories, Bar Harbor, ME) 
were used for subcutaneous injection of tumor cells with or without CAMs. 
Gastric cancer cells (MKN45, 5  105) were injected alone, alone on the left 
flank and together with 2  105 myofibroblasts on the right flank (groups 1 and 
2, respectively), or with TGFβig-h3 (1 µg per mouse per day) from day 0 by 
Alzet pump (groups 3 and 4, respectively). In a subset of the co-injected group, 
tumors were allowed to grow for 2 weeks before treatment with TGFβig-h3. 
Tumor size was monitored every 3 days for 4 weeks. Tumors were dissected, 
measured, fixed in 10% formalin or 4% paraformaldehyde (PFA), embedded 
in paraffin or OTC for frozen sections, and processed for hematoxylin/eosin 
staining or localization of α-SMA, using ABC avidin–biotin–DAB detection 
kit (Vector Labs) according to the supplied protocol.
Statistics
Results are expressed as mean ± standard error of the mean, unless otherwise 
stated. Student’s t-test or analysis of variance (ANOVA; Systat Software Inc., 
Hounslow, London, UK) as appropriate was used to determine statistical sig-
nificance of results and considered significant at P < 0.05, unless otherwise 
stated (see above for the statistical analysis of the proteomic data).
Results
Increased migration and proliferation of gastric cancer-derived 
myofibroblasts
The primary gastric tumors employed in this study exhibited increased 
numbers of myofibroblasts typically with disordered architecture and 
morphology compared with adjacent tissue or normal tissue (Supple-
mentary Figure 1, available at Carcinogenesis Online). Tissues adja-
cent to the tumor resection margin exhibited a range of morphologies 
including chronic gastritis (7), intestinal metaplasia (2) and intestinal 
metaplasia with atrophy (3) (Supplementary Table 1, available at Car-
cinogenesis Online).
Cultured myofibroblasts derived from normal tissue, cancer or tissue 
adjacent to gastric tumors all expressed α-SMA and vimentin but not 
desmin, and they were negative for pancytokeratin (Figure 1A). Basal 
rates of CAM migration in Boyden chambers were consistently greater 
than those of NTMs or their ATM counterparts (Figure 1B). Moreover, 
compared with their respective ATMs, CAMs also exhibited increased 
BrdU incorporation (Figure 1C), which was attributable to shorter G1 
phase of the cell cycle (Figure 1D). There was no difference in rates of 
apoptosis determined by cleaved caspase-3 staining (Figure 1C and E).
Stimulation of cancer cell proliferation and migration by cancer-
derived myofibroblasts
Interestingly, CM from both CAMs and ATMs, but not NTMs, 
resulted in epithelial–mesenchymal transition of gastric cancer AGS 
cells characterized by increased cell scattering (Figure 2A) and 
α-SMA expression (Figure 2B). Moreover, there was increased AGS 
cell migration (Figure 2C) and proliferation (Figure 2D) in response 
to CAM-CM and ATM-CM. The migration, invasion and prolifer-
ation responses to CAM-CM were consistently greater than those to 
their ATM counterparts. When CAMs were divided into groups based 
on tumor depth (pT1-2 versus pT3-4) there was no difference in the 
effect of CM on AGS cell proliferation (not shown). However, when 
CAMs were separated into groups based on lymph node involvement 
(pN0-1 versus pN2-4) the stimulation of 3[H]-thymidine incorpor-
ation was greater in response to CM from CAMs of patients with high 
lymph node involvement (Figure 2E).
Myofibroblast proteomes change during cancer progression
To identify proteins that might account for the different properties 
of CAMs compared with ATMs, we first examined the cellular 
proteomes of 11 pairs of cells using isobaric tagging for relative 
and absolute quantitation (iTRAQ) labeling followed by liquid 
chromatography–mass spectrometry/mass spectrometry (LC-MS/
MS) identification of labeled tryptic peptides (Supplementary Table 
2, available at Carcinogenesis Online). A total of 768 proteins 
were identified in at least 3 pairs of samples and a core set of 241 
proteins were identified in all 11 pairs which included proteins 
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Fig. 1. Increased migration and proliferation of cultured gastric cancer-associated myofibroblasts. (A) Positive α-SMA (green) and vimentin (red) staining in 
cultured myofibroblasts (nuclear staining with 4ʹ,6-diamidino-2-phenylindole, blue); top, CAMs; middle, ATMs; bottom, NTMs. (B) Increased migration of 
CAMs compared with ATMs and NTMs (left) in Boyden chambers, and individual pair-wise comparisons of CAMs versus their corresponding ATMs (right). 
(C) Increased BrdU labeling (left), but not apoptosis indicated by cleaved caspase-3 staining (right), in CAMs compared with ATMs and NTMs. (D) Shorter G1 
phase in CAMs compared with ATMs. (E) Individual pair-wise comparison of BrdU labeling and cleaved caspase-3 staining in CAMs versus their corresponding 
ATMs. Horizontal arrows, P < 0.05, ANOVA and n = 10–14.
Gastric myofibroblasts and cancer progression
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Fig. 2. Increased epithelial–mesenchymal transition, migration, invasion and proliferation of AGS cancer cells treated with CM from CAMs compared with 
ATMs. (A) Example of epithelial–mesenchymal transition characterized by scattering, α-SMA (green) and phalloidin staining (f-actin, red; nuclear staining 
with 4ʹ,6-diamidino-2-phenylindole, blue) in AGS cells treated with CM from NTMs (top) compared with CAMs (bottom). (B) Quantification of α-SMA-
positive AGS cells treated with CM from CAMs compared with ATMs and NTMs; a: P < 0.05 versus control, b: P < 0.05 versus NTM, c: P < 0.05 versus ATM 
(ANOVA). (C) Comparison of AGS cell migration (left) and invasion (right) in response to CM from paired samples of CAMs and ATMs. (D) 3[H]-thymidine 
incorporation in AGS cells treated with CM from CAMs compared with their matched ATMs. (E) 3[H]-thymidine incorporation in CAMs from patients with 
high (pN2-4) versus low or no (pN0-1) lymph node involvement; see Supplementary Methods, available at Carcinogenesis Online for details of the TNM 
classification. Horizontal arrows, ANOVA or t-test, *P < 0.05 and n = 10–14.
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that are putative myofibroblast markers including vimentin, cofilin 
and fibroblast activation protein-alpha (Supplementary Figure  2, 
available at Carcinogenesis Online) (36,37). Proteins exhibiting a 
significant difference in relative abundance were then analyzed by 
Metacore® (GeneGo) to identify Process Networks of differentially 
regulated interactions. Of 168 possible Process Networks, 39 were 
identified as significantly influenced. However, only one of these was 
significant in all 11 pairs of CAMs and ATMs (Supplementary Figure 
3 and Supplementary Table 3, available at Carcinogenesis Online), 
namely the involvement of actin filaments, which is consistent with 
the observed differences between CAMs and ATMs in cell migration 
assays.
Fig. 3. Identification of TGFβig-h3 as differentially expressed in CAMs. (A) Representative spectra showing, top, identification of one of the precursor 
peptides for a typical tryptic fragment (GDELADSALEIFK); middle, identification of fragments of the precursor peptide; bottom, isobaric tagging for relative 
and absolute quantitation reporter ions for this identification. (B) The sequence of TGFβig-h3 showing in red the coverage of tryptic peptides identified in a 
representative sample; functional domains of the protein are underlined. (C) Representative western blots of TGFβig-h3 in media of CAMs and ATMs from 
patients with high (pN2-4) (right side) versus low or no (pN0-1) (left side) lymph node involvement showing depressed abundance in CAMs from the former.
Gastric myofibroblasts and cancer progression
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The contribution of myofibroblast secretomes to the tumor 
microenvironment
In order to identify directly the secreted proteins that might account 
for the properties of CAM CM, we then applied iTRAQ labeling fol-
lowed by LC-MS/MS to myofibroblast media. Taking the secretomes 
of 11 pairs of CAMs and ATMs together, we identified 167 proteins 
that were expressed in three or more pairs of cells. Of these, 76 were 
considered secreted proteins using UniProt as the main database of 
which the largest categories were ECM proteins, proteases, binding 
proteins and ligands (Supplementary Figure 4, available at Carcino-
genesis Online). Proteins exhibiting a differential abundance in CAMs 
versus ATMs varied between 12 and 42% of the total (Supplementary 
Table 4, available at Carcinogenesis Online). Interestingly, many of 
the differentially abundant proteins were decreased in CAMs, and 
included protease inhibitors and ECM-related proteins (Supplemen-
tary Table 4, available at Carcinogenesis Online). We then used Meta-
core® (with an MKN45 cell transcriptome as background) to identify 
candidate responses in cancer cells as a consequence of the differ-
ences in myofibroblast secretomes. Significant differences were found 
in 17 of 168 possible networks, of which 3 were significant in all 11 
pairs of CAMs and ATMs (Supplementary Figure 5, available at Car-
cinogenesis Online). Importantly, given the biological properties of 
CM from CAMs in stimulating cancer cell invasion and migration, the 
three networks were associated with cell–matrix interactions, ECM 
remodeling and ECM degradation.
Secreted TGFβig-h3 from myofibroblast is linked to lymph node 
involvement and survival
We next analyzed the secretome data to identify candidate proteins 
exhibiting differences in abundance in CAMs from patients divided 
on the basis of low or no lymph node involvement (pN0-1) versus 
high lymph node involvement (pN2-4). The patients with high lymph 
node involvement had significantly shorter survival (9.6 ± 3.1 months) 
compared with patients with low or no lymph node involvement 
(44.0 ± 5.5  months, P < 0.05). Strikingly, in the dataset as a whole 
only a single protein, TGFβig-h3, exhibited a robust difference 
between the two groups (Fisher exact test with false discovery rate 
correction for multiple comparisons). Furthermore, TGFβig-h3 was 
one of the nodes in the cell–matrix interactions network, and also had 
interactions with nodes from the ECM remodeling and ECM degrada-
tion networks; thus, changes in TGFβig-h3 potentially influence all 
three of these signaling networks. The demonstration of TGFβig-h3 
as decreased in CAMs from patients with high lymph node involve-
ment was made on the basis of identification in all media samples with 
similar coverage in CAM and ATM samples (Figure 3B; Supplemen-
tary Table 5, available at Carcinogenesis Online). The finding was 
confirmed by western blot of media which revealed bands of approxi-
mately 68 and 72 kDa with decreased abundance in CAM media from 
patients with high lymph node involvement (Figure 3C).
TGFβig-h3 inhibits myofibroblast and cancer cell migration
To examine the consequence of TGFβig-h3 secretion by myofibro-
blasts, we then studied effects on cell migration and proliferation. 
Thus, TGFβig-h3 produced a concentration-dependent inhibition of 
IGF-II-stimulated migration of both myofibroblasts and AGS cells in 
Boyden chambers (Figure 4A). Similarly, IGF-II-stimulated myofi-
broblast and cancer cell proliferation was inhibited by TGFβig-h3 
(1  µg/ml; Figure 4B). There was also increased cleaved caspase-3 
in both myofibroblasts and cancer cells in response to TGFβig-h3 
( Figure 4C); in the former, we showed associated increases in Bax 
and Bim, and decreased Bcl2, by western blot (Figure 4D).
To test whether TGFβig-h3 in myofibroblast media restrained IGF-
II-stimulated migration, we examined the effects of siRNA knock-
down. Treatment of myofibroblasts with TGFβig-h3 siRNA reduced 
the abundance of TGFβig-h3 detected by western blot of cell extracts 
by 64%, but did not change the abundance of another ECM protein, 
decorin, used as a negative control (Supplementary Figure 6, available 
at Carcinogenesis Online). In siRNA-treated cells, the stimulation of 
migration by IGF-II was enhanced indicative of an autocrine stimu-
latory role for IG-II (Figure 5A). To determine whether TGFβig-h3 
released from myofibroblasts influenced cancer cell migration, we 
then examined CM from ATMs after prior treatment with TGFβig-h3 
siRNA or control oligonucleotides. The stimulatory effect of myofi-
broblast CM on AGS cell migration was increased after TGFβig-h3 
knockdown (Figure 5B), indicating that release of TGFβig-h3 inhibits 
growth factor-stimulated migration of both cancer cells and myofibro-
blasts. To elucidate the signaling pathways involved, we looked at the 
involvement of kinases downstream of the IGF-I receptor. Inhibition 
of p42/44 (U0126) activation significantly reduced IGF-II-stimulated 
myofibroblast migration and there was a smaller inhibition by a p38 
kinase inhibitor (SB202190; Figure 5C), whereas the PI3-kinase 
(LY294002) and Jun-kinase (JNK-II) inhibitors had no or little effect; 
similar results were obtained in AGS cells (Supplementary Figure 7, 
available at Carcinogenesis Online). TGFβig-h3 inhibited IGF-II-
stimulated phosphorylation of p42/44 kinase (Figure 5D).
TGFβig-h3 inhibits tumor growth in vivo
Finally, we asked whether TGFβig-h3 inhibited tumor growth in vivo 
using a xenograft model. For these studies, we used MKN45 cells 
that reproducibly establish tumors in a xenograft model and selected 
a CAM line (patient 3) that in preliminary studies stimulated MKN45 
cell growth when coinjected in xenografts. Tumor growth after 4 weeks 
of MKN45 cells co-injected with CAMs (right side) was completely 
inhibited when TGFβig-h3 was administered for the duration of the 
experiment (Figure 6A and B). Moreover, there was even a reduc-
tion of approximately 85% of increased tumor mass when TGFβig-h3 
was administered 2 weeks after the start of the experiment. There was 
no effect of TGFβig-h3 on tumor growth when MKN45 cells were 
injected in the absence of myofibroblasts, indicating that TGFβig-h3 
prevents stromal cell-stimulated tumor growth even in established 
tumors. Interestingly, the TGFβig-h3-treated tumors exhibited more 
necrosis and less α-SMA-positive cells than their untreated counter-
parts (Figure 6A).
Discussion
Stromal cells drive tumor growth by multiple mechanisms influencing 
angiogenesis, inflammation and immune responses, as well as direct 
effects on tumor cells (12,14,37). We show here that gastric CAMs, 
which are a subset of CAFs, stimulate migration, proliferation and 
invasion of tumor cells compared with ATMs or NTMs; there are dif-
ferences in the cellular proteomes and secretomes of CAMs and ATMs 
and we identify decreased secretion of the ECM protein TGFβig-h3 in 
CAMs from patients with high lymph node involvement and shorter 
survival. Cell migration and proliferation in response to IGF stimu-
lation are inhibited by TGFβig-h3. Moreover, in a xenograft model, 
administration of TGFβig-h3 slows stroma-stimulated tumor growth. 
Thus, stromal cell secretion of an ECM protein provides a mechanism 
to inhibit tumor growth which is lost with tumor progression, indicat-
ing that stromal cells exhibit protective as well as aggressive properties.
There are differences in number, architecture and morphology of 
gastric CAMs compared with ATMs and NTMs; there are also func-
tional differences when these cells are cultured. In principle, it is 
possible that cultured myofibroblasts might be unstable, but at least 
up to 10 passages we have found both the functional properties and 
molecular profiles of these cells to be stable. It becomes possible, 
then, to perform both functional studies and molecular profiling of 
secreted proteins in the same cells and to relate the findings to clinical 
data on cancer status. Although studies of stromal cell transcriptomes 
and proteomes can be carried out on microdissected tumor tissue, this 
approach does not lend itself to either concomitant functional studies 
in the same cells or kinetic analysis of the secreted proteins which 
determine the tumor microenvironment. These data indicate that 
in both cellular proteomes and in secretomes, there are  differences 
between gastric CAMs and their corresponding ATMs consistent with 
observed functional differences, notably increased migration and inva-
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sion by CAMs and by CAM CM applied to tumor cells. Moreover, a 
comparison of myofibroblast secretomes in patients with high versus 
low or no lymph node involvement revealed decreases in the ECM 
adaptor protein TGFβig-h3 in CAMs from advanced gastric tumors. 
The mechanism underlying loss of TGFβig-h3 remains uncertain, 
although examination of a microarray dataset indicates that mRNA 
abundance is unchanged (data not shown). This study was not designed 
to address differences in myofibroblast biology with respect to either 
tumor type (e.g. intestinal versus diffuse), or in preneoplastic changes 
(e.g. chronic gastritis, intestinal metaplasia and atrophy); nevertheless, 
Fig. 4. Inhibition of myofibroblast and cancer cell proliferation and migration by TGFβig-h3 and stimulation of apoptosis. (A) Concentration-dependent inhibition 
of IGF-II (100 ng/ml)-stimulated myofibroblast and AGS cell migration by TGFβig-h3. (B) TGFβig-h3 (1 µg/ml) inhibition of IGF-II-stimulated myofibroblast, AGS 
and MKN45 cell proliferation determined by EdU incorporation. (C) TGFβig-h3 increased caspase-3 staining of myofibroblast, AGS and MKN45 cells.  
(D) TGFβig-h3 increased Bax and Bim in myofibroblasts detected by western blot and decreased Bcl-2. Horizontal arrows, ANOVA or t-test, *P < 0.05 and n = 3.
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our findings suggest that it is now both feasible and worthwhile to 
address these issues.
Myofibroblasts are well known to contribute to the deposition of 
ECM (38,39). These studies of myofibroblast secretomes indicate, 
however, that while some ECM proteins are increased in CAMs, others 
are decreased. Moreover, these differences are exaggerated in CAMs 
from patients with high lymph node involvement and poor survival, 
suggesting changes in CAM function as the disease progresses. In par-
ticular, there is an overall loss of diversity in the secretome with cancer 
progression and analysis of interaction networks indicates that these 
predict changes in cell behavior corresponding to functional changes 
observed in vivo notably with respect to cell migration and invasion.
It is only quite recently that proteomic approaches have been 
applied to the analysis of stromal cell secretomes (40). The identifi-
cation of TGFβig-h3 as significantly decreased in the secretome of 
CAMs from patients with high lymph node involvement and short 
survival suggests a new dimension to the role of this protein in can-
cer. TGFβig-h3 was originally identified as a TGFβ-induced gene 
in the lung adenocarcinoma cell line A549 (26). There is accumu-
lation of TGFβig-h3 at sites of inflammation and wound healing 
and it is thought to play a role in adhesion as a ligand of several 
integrins and by binding to collagen and other ECM proteins (27). 
Mutations of TGFβig-h3 are associated with corneal dystrophies 
(41,42), but its role in cancer is still unclear. Over-expression of 
TGFβig-h3 in Chinese hamster ovary cells decreased their tumor-
forming capacity in nude mice (28), and a tumor suppressor func-
tion is indicated by the observation that mice null for TGFβig-h3 
exhibit spontaneous tumors in a number of organs (29). Similarly, 
expression of TGFβig-h3 in ovarian cancer cells and in non-small 
cell lung cancer cells is associated with sensitivity to chemotherapy 
(30,43), and expression in neuroblastoma (44), lung and breast can-
cer cells (45,46) has been associated with decreased tumorigenic-
ity. Conversely, however, TGFβig-h3 has been reported to promote 
invasion of colon and ovarian cancer cells (31,32,47). These studies 
have focused on the expression of TGFβig-h3 in tumor cells, and 
present finding of changes in stromal cell production of TGFβig-h3 
indicates a more complex role than supposed previously.
These data show that TGFβig-h3 alone had little or no effect on 
myofibroblast or cancer cell proliferation and migration, although there 
was some stimulation of apoptosis. However, TGFβig-h3 strongly 
inhibited IGF-II-stimulated migration and proliferation of both cell 
types; knockdown of TGFβig-h3 expression increased the stimula-
tory effect of myofibroblast CM on cell migration; and in a xenograft 
model of myofibroblast-stimulated tumor growth, TGFβig-h3 had an 
inhibitory effect. The latter experiments employed SCID mice which 
have deficiencies in T- and B-cell maturation, making it unlikely that an 
immune response to TGFβig-h3 was involved. Moreover, the response 
to TGFβig-h3 is distinct from that to other proteins used in the same 
model (25). Previous work has established that gastric myofibroblasts 
produce IGF-II that can act as both an autocrine growth factor and a 
Fig. 5. Enhanced migration of myofibroblasts and AGS cells after knockdown of TGFβig-h3. (A) TGFβig-h3 siRNA knockdown (TGFβig-h3-KO) increased 
IGF-II (100 ng/ml)-stimulated myofibroblast migration. (B) CM from TGFβig-h3 siRNA-treated myofibroblasts increased AGS cell migration compared with 
CM from cells treated with control oligonucleotides. (C) IGF-II-stimulated myofibroblast migration is inhibited by U0126 (UO, 10 µM) and SB202190 (SB, 
3 µM) but not LY294002 (LY, 50 µM) and JNK-II (JNK, 50 µM). (D) Representative western blot showing phosphorylation of p42/44 kinase was inhibited by 
TGFβig-h3. Horizontal arrows, *P < 0.05 and n = 3.
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paracrine stimulant of gastric epithelial cell proliferation and migra-
tion (23). The present findings extend this by showing that there are 
functional differences between CAMs and ATMs, and between CAMs 
based on tumor stage, in response to IGF-II. Moreover, inhibition of 
these effects by exogenous and endogenously generated TGFβig-h3 
indicates that there is a dynamic equilibrium between stimulatory 
effects of IGF-II and inhibitory effects of TGFβig-h3 generated by 
stromal cells, that is lost in cancer progression. Interactions between 
TGFβig-h3 and IGF-II appear to occur proximal to activation of p42/44 
MAPkinase which mediates the effects of IGF-II. There are RGB and 
FAS1 domains in TGFβig-h3 that mediate integrin binding; since there 
are well-recognized interactions between ECM proteins, integrins and 
IGF-receptor signaling (48), we suggest that the inhibitory action of 
TGFβig-h3 is exerted at this level.
Taken together, these data show myofibroblasts from gastric cancer 
differ from those from adjacent tissue in stimulating cancer cell prolif-
eration, migration and invasion. By focusing on CAM secretomes, we 
have identified an unexpected role for myofibroblasts in restraining 
tumor migration and proliferation in early disease through secretion 
of TGFβig-h3. Depression of TGFβig-h3 secretion by myofibroblasts 
occurs with tumor progression and could provide a novel functional 
biomarker for stromal cell properties in cancer. Since TGFβig-h3 had 
Fig. 6. Inhibitory effects of TGFβig-h3 in a xenograft model of stromal-stimulated tumor growth. (A) Representative images of α-SMA localization in 
xenografts and (B) quantification and statistical analysis of tumor volume. Mice were treated with TGFβig-h3 (1 µg per mouse per day) either for the whole 
duration of the experiment (4 weeks) or after 2 weeks of tumor growth. Treated xenografts were compared with untreated xenografts with and without 
co-injection of CAMs with MKN45 cells as appropriate. n = 5 per group, *P < 0.05 and Dunnett for multiple comparisons; all data are represented as mean ± 
standard error of the mean.
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a suppressive effect in a xenograft model of stroma-stimulated cancer 
growth, we suggest that it may also be possible to develop novel thera-
peutic strategies based on the observation that stromal cell-stimulated 
tumor growth in vivo is prevented by restoration of TGFβig-h3.
Supplementary material
Supplementary methods and Supplementary Tables 1–5 and  Figures 
1–7 can be found at http://carcin.oxfordjournals.org/.
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